Literature DB >> 19375064

CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Daniele Marrelli1, Stefano Caruso, Corrado Pedrazzani, Alessandro Neri, Eduardo Fernandes, Mario Marini, Enrico Pinto, Franco Roviello.   

Abstract

BACKGROUND: Obstructive jaundice is frequently associated with false CA19-9 elevation in benign conditions. The diagnostic accuracy of this tumor marker was evaluated in the present longitudinal study.
METHODS: In 128 patients admitted for obstructive jaundice (87 with pancreato-biliary malignancy and 41 benign disease) serum CA19-9 was measured. Statistical analysis of marker levels obtained before and after endoscopic biliary drainage was performed in 60 patients.
RESULTS: Elevated CA19-9 levels (>37 U/mL) were found in 61% of benign cases and 86% of malignancies. After biliary drainage, decrease of serum CA19-9 was observed in 19 of 38 malignant cases and in almost all benign cases (Wilcoxon matched pairs test: P = .207 and P <.001, respectively). Receiver operating characteristic (ROC) analysis identified a cut-off value of 90 U/mL to be associated with improved diagnostic accuracy after biliary drainage (sensitivity 61%, specificity 95%).
CONCLUSIONS: In the presence of successfully drained obstructive jaundice, CA19-9 serum levels that remain unchanged or measure more than 90 U/mL are strongly indicative of a malignant cause of obstruction. However, the real clinical utility of this marker remains controversial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375064     DOI: 10.1016/j.amjsurg.2008.12.031

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  69 in total

1.  Pancreatic Cancer: a Challenge to Cure.

Authors:  M Tewari
Journal:  Indian J Surg       Date:  2015-10-19       Impact factor: 0.656

Review 2.  Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Authors:  Marta Herreros-Villanueva; Luis Bujanda
Journal:  Ann Transl Med       Date:  2016-04

3.  Ca19-9 and pancreatic cancer: Is it really that good?

Authors:  Gareth Morris-Stiff; Mark A Taylor
Journal:  J Gastrointest Oncol       Date:  2012-06

4.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

5.  Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.

Authors:  Udayakumar Navaneethan; Vennisvasanth Lourdusamy; Earl Poptic; Jeffrey P Hammel; Madhusudhan R Sanaka; Mansour A Parsi
Journal:  Dig Dis Sci       Date:  2014-10-25       Impact factor: 3.199

6.  Autoimmune pancreatitis misdiagnosed as a tumor of the head of the pancreas.

Authors:  Eran Brauner; Jesse Lachter; Offir Ben-Ishay; Euvgeni Vlodavsky; Yoram Kluger
Journal:  World J Gastrointest Surg       Date:  2012-07-27

7.  Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.

Authors:  Claire Jenkinson; Victoria L Elliott; Anthony Evans; Lucy Oldfield; Rosalind E Jenkins; Darragh P O'Brien; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Evangelia-O Fourkala; Ian J Jacobs; Usha Menon; Trevor Cox; Fiona Campbell; Stephen P Pereira; David A Tuveson; B Kevin Park; William Greenhalf; Robert Sutton; John F Timms; John P Neoptolemos; Eithne Costello
Journal:  Clin Cancer Res       Date:  2015-11-16       Impact factor: 12.531

8.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

Review 9.  Strategies for early detection of resectable pancreatic cancer.

Authors:  Keiichi Okano; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.

Authors:  Preethi G K Venkatesh; Udayakumar Navaneethan; Bo Shen; Arthur J McCullough
Journal:  Dig Dis Sci       Date:  2012-09-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.